Publication date: Jul 01, 2025
Previous studies have demonstrated that repetitive transcranial magnetic stimulation (rTMS) can improve clinical symptoms of Parkinson’s disease (PD). Continuous theta-burst stimulation (cTBS) is a well-established rTMS protocol that affects brain neurons, reducing the excitability of the motor system. This study aims to explore the long-term effects of cTBS on improvement of movement symptoms in patients with PD. Patients who met the inclusion criteria were non-randomly assigned to either the cTBS group or control group. The cTBS group received rTMS interventions every 10 weeks, while the control group was treated solely with anti-Parkinson’s medications for symptom management. The study cycle lasted nearly one year, with data analysis conducted from March to May 2024. Linear mixed models were employed to analyze the primary outcome using the Unified Parkinson’s Disease Rating Scale (UPDRS) Part III. A total of 43 participants completed the 46-week study. The cTBS group demonstrated significant improvement in UPDRS III compared to the control group after the first intervention, maintaining this progress until the final follow-up, which correlated with changes in overall motor symptoms. Additionally, the cTBS group showed a significant decrease in H-Y scale, while the levodopa equivalent dose (LED) did not increase significantly. These findings implicated that cTBS can effectively alleviate motor symptoms of PD, and rTMS targeting left SMA may be a feasible and easy-to-implement non-drug intervention to slow the progressive decline in motor symptoms and quality of life in PD, providing a new option for PD treatment.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Parkinson’s disease |
| drug | DRUGBANK | Methionine |
| drug | DRUGBANK | Levodopa |
| pathway | KEGG | Parkinson disease |